DOCSLIB.ORG

Polycythemia Vera (PV)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Polycythemia Vera (PV) Symptoms of PV | How is PV Diagnosed? | How is PV treated? | | Underwriting Comment | Polycythemia Vera (PV) Polycythemia Vera (PV) is a bone marrow disease that results primarily in the over production of red blood cells (RBCs). In many patients the numbers of white blood cells and blood platelets are also elevated. The increase in RBCs and platelets can create serious and potentially fatal complications for the patient. In addition, PV can develop into chronic leukemia or other related bone marrow malignancies. The mean age of diagnosis of PV is 60 years with the male to female ratio being about 1.4:1. The "cause" of PV is an acquired mutation of the DNA in the bone marrow. An abnormal "stem cell" shifts into overdrive and out produces the millions of other similar cells in the marrow. The mutant cell line comes to dominate blood cell production. The RBCs being produced by the mutant cells are nearly normal but they are made in excessive numbers. What are the symptoms of PV? Many patients with PV are without symptoms (called asymptomatic) and are first identified on a routine blood examination. If a patient has symptoms from PV, they are often related to the abnormally high number of blood cells. Symptoms usually come on gradually, and may include: Headache Weakness Fatigue Light-headedness or dizziness Itching, especially after a hot shower or bath Visual impairments Shortness of breath or trouble breathing A red color to the skin, especially in the face Abnormal bleeding Bone pain A blood clot in a vein, also called deep venous thrombosis About one fifth of patients with PV present with a clotting event such as a deep vein thrombosis, heart attack or a stroke. How is PV diagnosed? PV is diagnosed based on three primary criteria: 1. Elevated red blood cell (RBC) count 2. Normal oxygen blood gas reading (i.e. >92% oxygen in arterial blood with room air) 3. Enlargement of the spleen (called splenomega) In addition to the primary criteria above, the following "minor criteria" can also suggest PV: 1. Elevated platelet count 2. Elevated white blood cell (WBC) count 3. Elevated alkaline phosphatase level The standard test for determining the concentration of red cells, white cells and platelets in the blood is called a "complete blood cell count" or CBC. See this link for an excellent review of the basics of the CBC http://www.heartcenteronline.com/myheartdr/common/ articles.cfm?ARTID=205 Normal RBC count for women is 4.6 million cells Normal RBC count for men is 5.2 million cells In PV, the RBCs will be elevated. In addition, the actual percentage of RBCs in the blood will also be elevated. The test that measures the "level or percentage of RBC cells in the blood" is called the hematocrit. Normal hematocrit for women average 42% Normal hematocrit for men averages 47% Lastly there is the hemoglobin. Hemoglobin is the compound in RBCs that carries oxygen. Normal hemoglobin in women is 14 grams/100 milliliters. Normal hemoglobin in men is 16 grams/100 milliliters. At the time of diagnosis with PV, the hematocrit and hemoglobin concentration are increased in the same proportion as the RBCs. In addition to an increase in the RBCs, hematocrit and hemoglobin concentration, platelets are generally elevated. How is PV treated? Treatment of PV is based on the "rate of progression" of the disease (i.e. how quickly the RBCs and platelets are rising), the patient’s age and the presence of other medical problems. The primary goal of treatment is reduce the number of RBCs to near normal levels. If the platelet count is high, it will also require treatment. The following are treatments used in PV: Phlebotomy This is the removal of blood similar to a blood donation. It is generally the first step in the treatment of PV. A volume of blood is withdrawn at regular intervals with the goal of decreasing the number of RBCs for a period of weeks to months. This may be the sole form of treatment for many PV patients for years. When phlebotomy is the sole treatment for PV, the average rate of survival is extended more than 12 years. Drug Therapy Aspirin is used to reduce blood clots by making platelets less "sticky." Anagredlide (brand name Agrylin) is used to lower the platelet count (see this link for an overview of anagredlide http://www.nlm.nih.gov/medlineplus/druginfo/ anagrelidesystemic203493.html). Hydroxyurea (brand name Hydrea) is used with or without phlebotomy to suppress bone marrow production of RBCs and platelets (see this link for an overview of hydroxurea http:/ /www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682004.html). Chlorambucil (brand name Leukeran) is used with or without phlebotomy to suppress bone marrow production of RBCs and platelets (see this link for an overview of chlorambucilhttp://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682899.html ). Interferon-alpha is used with patients who cannot tolerate hydroxurea or for whom the medication stops working. Radiotherapy Radiotherapy is the form of radioactive phosphorus can be given in a liquid form to older patients. One or two treatments may decrease RBC and platelet production reducing the need for phlebotomy or drugs for long periods. Adding bone marrow suppressing medications (i.e. Hydrea or Leukeran) or radiotherapy to phlebotomy appears to reduce survival time as well increases the risk of patients developing acute leukemia. Underwriting Comment Clients with PV are insurable but under specific conditions. It is important to remember that symptomatic patients who go untreated have life expectancy of 18 months. Clients with PV who are insurable must be able to verify clinical stability. This includes a white blood count of less than 14,000 and a platelet count less than 500,000. In addition they must be in the first ten (10) years of the disease. Clients with PV longer than ten years duration may be insurable, but are considered on an individual basis. Use the following questions to screen clients with PV: 1. When was the client diagnosed with PV? Treatment clearly extends the life expectancy of clients with PV but the duration of the disease is a crucial piece of underwriting information. 2. What type of treatment (s) is the client undergoing to manage their PV? Is the client being treated with phlebotomy alone or are medications being used? 3. Are the client’s RBCs, WBCs and platelets close to normal range? Most clients with PV either know or can find out this information. 4. Has the client has any complication from their PV? This includes a history of deep vein blood clots, visual problems, and lung and heart problems. 5. Does the client currently smoke? PV is enough of an increased risk factor for clotting complications without adding in the complication of smoking. Clients with PV who continue to smoke are considered a poor risk for individual coverage. 6. Does the client have any other medical problems? 7. Does the client take any other medications? © Copyright 2002, RiskTutor Inc..
Load more

Recommended publications
  • Updates in Mastocytosis
    Updates in Mastocytosis Tryptase PD-L1 Tracy I. George, M.D. Professor of Pathology 1 Disclosure: Tracy George, M.D. Research Support / Grants None Stock/Equity (any amount) None Consulting Blueprint Medicines Novartis Employment ARUP Laboratories Speakers Bureau / Honoraria None Other None Outline • Classification • Advanced mastocytosis • A case report • Clinical trials • Other potential therapies Outline • Classification • Advanced mastocytosis • A case report • Clinical trials • Other potential therapies Mastocytosis symposium and consensus meeting on classification and diagnostic criteria for mastocytosis Boston, October 25-28, 2012 2008 WHO Classification Scheme for Myeloid Neoplasms Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia Atypical Chronic Myeloid Leukemia Juvenile Myelomonocytic Leukemia Myelodysplastic Syndromes MDS/MPN, unclassifiable Chronic Myelogenous Leukemia MDS/MPN Polycythemia Vera Essential Thrombocythemia Primary Myelofibrosis Myeloproliferative Neoplasms Chronic Neutrophilic Leukemia Chronic Eosinophilic Leukemia, NOS Hypereosinophilic Syndrome Mast Cell Disease MPNs, unclassifiable Myeloid or lymphoid neoplasms Myeloid neoplasms associated with PDGFRA rearrangement associated with eosinophilia and Myeloid neoplasms associated with PDGFRB abnormalities of PDGFRA, rearrangement PDGFRB, or FGFR1 Myeloid neoplasms associated with FGFR1 rearrangement (EMS) 2017 WHO Classification Scheme for Myeloid Neoplasms Chronic Myelomonocytic Leukemia Acute Myeloid Leukemia Atypical Chronic Myeloid Leukemia Juvenile Myelomonocytic
    [Show full text]
  • Treatment Approaches to Polycythemia Vera and Myelofibrosis
    REVIEW ARTICLE Rev Hematol Mex. 2016 Apr;17(2):129-138. Treatment approaches to polycythemia vera and myelofibrosis. Palmer J, Mesa R Abstract Myeloproliferative neoplasms consist of a diverse group of disorders. Over the last 10 years, with better understanding of pathophysiology of these disorders, there are many more treatment options available to patients with these diseases. Further, improved understanding of the underlying genetic landscape has led to improved prognostication which helps identify appropriate therapeutic options. For polycythe- mia vera, initial therapy generally includes aspirin and phlebotomy. However, in patients who do not achieve an appropriate response to phlebotomy, hydroxyurea or ruxolitinib can be considered. In patients who have myelofibrosis, therapy is determined by symptom burden. In patients who have significant constitutional symptoms, a JAK inhibitor, such as ruxolitinib is an appropriate choice. There are many novel therapies under investigation for patients with myelofibrosis, including anti-fibrotic agents, novel JAK inhibitors, telomerase inhibitors and allogeneic stem cell transplant. KEYWORDS: polycythemia vera; myelofibrosis; treatment Rev Hematol Mex. 2016 abr;17(2):129-138. Enfoques terapéuticos de policitemia vera y mielofibrosis Palmer J, Mesa R Resumen Las neoplasias mieloproliferativas consisten en un diverso grupo de enfermedades. En los últimos 10 años, con mejor comprensión de estas enfermedades, hay mas opciones de tratamiento disponibles para los pacientes que las padecen. Además, el mejor entendimiento del pano- rama genético detrás de estas enfermedades ha contribuido a mejorar el pronóstico, lo que ayuda a identificar las opciones terapéuticas Mayo Clinic, Phoenix AZ, USA. adecuadas. El tratamiento inicial de la policitemia vera generalmente incluye aspirina y flebotomía.
    [Show full text]
  • Section 8: Hematology CHAPTER 47: ANEMIA
    Section 8: Hematology CHAPTER 47: ANEMIA Q.1. A 56-year-old man presents with symptoms of severe dyspnea on exertion and fatigue. His laboratory values are as follows: Hemoglobin 6.0 g/dL (normal: 12–15 g/dL) Hematocrit 18% (normal: 36%–46%) RBC count 2 million/L (normal: 4–5.2 million/L) Reticulocyte count 3% (normal: 0.5%–1.5%) Which of the following caused this man’s anemia? A. Decreased red cell production B. Increased red cell destruction C. Acute blood loss (hemorrhage) D. There is insufficient information to make a determination Answer: A. This man presents with anemia and an elevated reticulocyte count which seems to suggest a hemolytic process. His reticulocyte count, however, has not been corrected for the degree of anemia he displays. This can be done by calculating his corrected reticulocyte count ([3% × (18%/45%)] = 1.2%), which is less than 2 and thus suggestive of a hypoproliferative process (decreased red cell production). Q.2. A 25-year-old man with pancytopenia undergoes bone marrow aspiration and biopsy, which reveals profound hypocellularity and virtual absence of hematopoietic cells. Cytogenetic analysis of the bone marrow does not reveal any abnormalities. Despite red blood cell and platelet transfusions, his pancytopenia worsens. Histocompatibility testing of his only sister fails to reveal a match. What would be the most appropriate course of therapy? A. Antithymocyte globulin, cyclosporine, and prednisone B. Prednisone alone C. Supportive therapy with chronic blood and platelet transfusions only D. Methotrexate and prednisone E. Bone marrow transplant Answer: A. Although supportive care with transfusions is necessary for treating this patient with aplastic anemia, most cases are not self-limited.
    [Show full text]
  • 3Rd Year BLOOD and IMMUNOLOGY II Study Guide
    BLOOD AND IMMUNOLOGY II MODULE STUDY GUIDE 3RD YEAR MBBS Contents Vision and Mission of KGMC ................................................................................................................................................................................................ Khyber Medical University: Vision ....................................................................................................................................................................................... Khyber Girls Medical College: Vision ................................................................................................................................................................................... Khyber Girls Medical College: Mission ............................................................................................................................................................................... Curriculum Committee KGMC .............................................................................................................................................................................................. Module committee ............................................................................................................................................................................................................... Outcomes of the curriculum: ..............................................................................................................................................................................................
    [Show full text]
  • Polycythemia Vera Cancer Cluster Investigation in Northeast PA
    Polycythemia Vera Cancer Cluster Investigation in Northeast PA Environmental toxic substances found historically in the PV cluster area and their potential for inducing DNA damage Investigating PV What is PV? PV is one of the diseases known as MPNs (myeloproliferative neoplasms). MPNs are a group of blood cancers where the bone marrow makes too many blood cells. Other illnesses included in this group of diseases are essential thrombocytosis (ET) and primary myelofibrosis (PMF). How does the body make blood cells? The body’s bone marrow contains billions of cells, but only a very tiny group plays a key role in forming blood cells (hematopoiesis). This group is composed of hematopoietic stem cells, which provide the body with a constant supply of all types of blood cells throughout life. What causes PV? The cause of PV is unknown. Scientists do know that a gene mutation (called the JAK2V617F mutation or “JAK2”) occurs in about 97% of PV cases. A gene mutation is a permanent change in the DNA sequence that makes up a gene inside the cells of a person’s body. The causes of the JAK2 mutation are also unknown. What is the history of the ATSDR PV investigation? • In 2005, local physicians and community members in Carbon, Luzerne, and Schuylkill counties raised concerns about the diagnosis of four cases of PV on the same rural road in the area where the three counties come together. • Residents also raised concerns about possible historical and current exposures to hazardous chemicals from various locations in the tri-county area. • The Pennsylvania Department of Health asked ATSDR for help investigating the cases and pattern of PV in this area of northeast Pennsylvania.
    [Show full text]
  • Essential Thrombocythemia Polycythemia Vera
    n ESSENTIAL THROMBOCYTHEMIA n POLYCYTHEMIA VERA n MYELOFIBROSIS ADVOCACY & EDUCATION mpnadvocacy.com INTERNATIONAL mpnadvocacy.com MPN Advocacy & Education International MPN Advocacy and Education International provides educational programs, materials, Ann Brazeau, CEO and resources for patients, caregivers, physicians, and entire healthcare teams to improve their understanding of myelofibrosis, polycythemia vera, and essential thrombocythemia. They are dedicated to making a difference in the lives of those affected by MPNs and strive to grow awareness and advocate on behalf of the MPN community. Kathleen Michael Vice President Advocacy Our advocacy efforts extend beyond responding to the unmet needs of the MPN Community. We identify concerns in a meaningful and productive way and create initiatives that impact quality care, treatment access, new drug development and represent MPN patients and organizations who are unable to address the issues surrounding a blood cancer diagnosis. Women and MPN and Pediatric and Young Adult initiatives have expanded Dr. Ruben Mesa, MD, Scientific Advisor the interest and exploration into the unmet needs of these UT Health San Antonio patient groups. Cancer Center Education MPN Education programs are held across the country and internationally each year. Our speakers are MPN specialists who share updated information on research, clinical trials, treatment options, and comprehensive quality of life direction. Dr. Ruben Mesa, MD, is our scientific advisor and frequent speaker at our educational programs. VIEW EVENTS Please visit our website at www.mpnadvocacy.com for more information on events, advocacy initiatives, patient support groups in your area and numerous resources. PAGE ONE What are Myeloproliferative Neoplasms (MPN)? Myelo – prefix referring to bone marrow Proliferative – increasing the numbers of cells Neoplasm – any new and abnormal growth, where cell multiplication is uncontrolled and progressive.
    [Show full text]
  • A Rapid and Quantitative D-Dimer Assay in Whole Blood and Plasma on the Point-Of-Care PATHFAST Analyzer ARTICLE in PRESS
    MODEL 6 TR-03106; No of Pages 7 ARTICLE IN PRESS Thrombosis Research (2007) xx, xxx–xxx intl.elsevierhealth.com/journals/thre REGULAR ARTICLE A rapid and quantitative D-Dimer assay in whole blood and plasma on the point-of-care PATHFAST analyzer Teruko Fukuda a,⁎, Hidetoshi Kasai b, Takeo Kusano b, Chisato Shimazu b, Kazuo Kawasugi c, Yukihisa Miyazawa b a Department of Clinical Laboratory Medicine, Teikyo University School of Medical Technology, 2-11-1 Kaga, Itabashi, Tokyo 173-8605, Japan b Department of Central Clinical Laboratory, Teikyo University Hospital, Japan c Department of Internal Medicine, Teikyo University School of Medicine, Japan Received 11 July 2006; received in revised form 7 December 2006; accepted 28 December 2006 KEYWORDS Abstract The objective of this study was to evaluate the accuracy indices of the new D-Dimer; rapid and quantitative PATHFAST D-Dimer assay in patients with clinically suspected Deep-vein thrombosis; deep-vein thrombosis (DVT). Eighty two consecutive patients (34% DVT, 66% non-DVT) Point-of-care testing; with suspected DVT of a lower limb were tested with the D-Dimer assay with a Chemiluminescent PATHFAST analyzer. The diagnostic value of the PATHFAST D-Dimer assay (which is immunoassay based on the principle of a chemiluminescent enzyme immunoassay) for DVT was evaluated with pre-test clinical probability, compression ultrasonography (CUS). Furthermore, each patient underwent contrast venography and computed tomogra- phy, if necessary. The sensitivity and specificity of the D-Dimer assay using 0.570 μg/ mL FEU as a clinical cut-off value was found to be 100% and 63.2%, respectively, for the diagnosis of DVT, with a positive predictive value (PPV) and negative predictive value (NPV) of 66.7% and 100%, respectively.
    [Show full text]
  • Introduction to Hematological Assessment (PDF)
    UPDATED 01/2021 Introduction to Hematological Assessment Objectives After completing this lesson, you will be able to: • State the main purposes of a hematological assessment. • Explain the procedures for collecting and processing a blood sample. • Understand the importance of hand washing. • Understand the importance of preventing blood borne pathogen transmission. • Describe and follow the hemoglobin test procedure using the Hemocue Hemoglobin Analyzer. Overview The most common form of nutritional deficiency is “iron deficiency”. It is observed more frequently among children and women of childbearing age (particularly pregnant women). Iron deficiency can result in developmental delays and behavioral disturbance in children, as well as increased risk for a preterm delivery in pregnant women. Iron status can be determined using several different types of laboratory tests. The two tests most commonly used to screen for iron deficiency are hemoglobin (Hgb) concentration and hematocrit (Hct). Proper screening for iron deficiency requires sound laboratory methods and procedures. Often, CPAs will hear the following questions: “Do you have to stick my finger? What does this have to do with my WIC foods anyway? Will it hurt?” For most of us, the thought of having blood taken, even from a finger, is not pleasant. However, evaluating the results of a blood test is a part of screening for nutritional risk. Why Does WIC Require Hematological Assessment? WIC requires that each applicant be screened for risk of a medical condition known as iron deficiency anemia. Anemia is a condition of the blood in which the amount of hemoglobin falls below a level considered desirable for good health.
    [Show full text]
  • Your Blood Cells
    Page 1 of 2 Original Date The Johns Hopkins Hospital Patient Information 12/00 Oncology ReviseD/ RevieweD 6/14 Your Blood Cells Where are Blood cells are made in the bone marrow. The bone marrow blood cells is a liquid that looks like blood. It is found in several places of made? the body, such as your hips, chest bone and the middle part of your arm and leg bones. What types of • The three main types of blood cells are the red blood cells, blood cells do the white blood cells and the platelets. I have? • Red blood cells carry oxygen to all parts of the body. The normal hematocrit (or percentage of red blood cells in the blood) is 41-53%. Anemia means low red blood cells. • White blood cells fight infection. The normal white blood cell count is 4.5-11 (K/cu mm). The most important white blood cell to fight infection is the neutrophil. Forty to seventy percent (40-70%) of your white blood cells should be neutrophils. Neutropenia means your neutrophils are low, or less than 40%. • Platelets help your blood to clot and stop bleeding. The normal platelet count is 150-350 (K/cu mm). Thrombocytopenia means low platelets. How do you Your blood cells are measured by a test called the Complete measure my Blood Count (CBC) or Heme 8/Diff. You may want to keep track blood cells? of your blood counts on the back of this sheet. What When your blood counts are low, you may become anemic, get happens infections and bleed or bruise easier.
    [Show full text]
  • Blood Donor Information
    Blood Donor Information Thank you for coming to donate blood. We are Did you know that some causes sorry that we cannot accept you as a donor today of anemia are invisible? because your hematocrit level was too low. You may not know you have bleeding from We care about your health and want to help you your digestive tract. This can be a result of: understand what having a low hematocrit level means.You are not alone, having a low hematocrit • Stomach ulcers level is the most frequent cause for not being able • Growths in intestines (polyps) to donate blood. You may return to donate when • Colon cancer your hematocrit level has increased and you can • Certain medications help immediately by asking your friends, family • Other diseases of the digestive tract and/or coworkers to donate. There are several Anemia is often the first symptom of these simple ways to improve your hematocrit level. conditions so it should be taken seriously. If you feel You may be eligible to donate another time. you don’t fit in any of the previous categories, What is Hematocrit? or just want to rule out these possibilities, make an appointment with your physician without delay. Blood is made up of red blood cells, white blood cells, platelets, and plasma. Hematocrit is the percentage of blood You should see your doctor if your volume that is red blood cells. Red blood cells contain hematocrit is low and you: hemoglobin which carries oxygen to all the cells in the body. • donate less than three times per year, Why do we test potential blood • are a non-menstruating woman of any donors for hematocrit levels? age with a hematocrit below 36%, Hematocrit is measured prior to each donation as part of • a man with a hematocrit less than 38%, and donor screening.
    [Show full text]
  • Essential Thrombocythemia Facts No
    Essential Thrombocythemia Facts No. 12 in a series providing the latest information for patients, caregivers and healthcare professionals www.LLS.org • Information Specialist: 800.955.4572 Introduction Highlights Essential thrombocythemia (ET) is one of several l Essential thrombocythemia (ET) is one of a related “myeloproliferative neoplasms” (MPNs), a group of closely group of blood cancers known as “myeloproliferative related blood cancers that share several features, notably the neoplasms” (MPNs) in which cells in the bone “clonal” overproduction of one or more blood cell lines. marrow that produce the blood cells develop and All clonal disorders begin with one or more changes function abnormally. (mutations) to the DNA in a single cell; the altered cells in l ET begins with one or more acquired changes the marrow and the blood are the offspring of that one (mutations) to the DNA of a single blood-forming mutant cell. Other MPNs include polycythemia vera and cell. This results in the overproduction of blood cells, myelofibrosis. especially platelets, in the bone marrow. The effects of ET result from uncontrolled blood cell l About half of individuals with ET have a mutation production, notably of platelets. Because the disease arises of the JAK2 (Janus kinase 2) gene. The role that this from a change to an early blood-forming cell that has the mutation plays in the development of the disease, capacity to form red cells, white cells and platelets, any and the potential implications for new treatments, combination of these three cell lines may be affected – and are being investigated. usually each cell line is affected to some degree.
    [Show full text]
  • Rethinking the Diagnostic Criteria of Polycythemia Vera
    Leukemia (2014) 28, 1191–1195 & 2014 Macmillan Publishers Limited All rights reserved 0887-6924/14 www.nature.com/leu REVIEW Rethinking the diagnostic criteria of polycythemia vera T Barbui1, J Thiele2, AM Vannucchi3 and A Tefferi4 The aim of this review is to critically address the validity and clinical applicability of three major diagnostic classification systems for polycythemia vera (PV), that is, those proposed by the Polycythemia Vera Study Group (PVSG), the British Committee for Standards in Haematology (BCSH) and the World Health Organization (WHO). Special focus is on which one of the three red cell parameters (hemoglobin—HB, hematocrit—HCT and red cell mass—RCM) should be used as the diagnostic hallmark of PV. The revised BCSH employed a persistently raised HCT level as the first diagnostic criterion in combination with the presence of a JAK2V617F mutation. On the other hand, the WHO classification used a raised HB value as a surrogate for increased RCM in association with molecular markers and for the first time, the bone marrow (BM) morphology was included as a minor criterion. Ongoing controversy and discussion regards the use of certain threshold values for HCT and HB as surrogates for RCM as well as the existence of prodromal- latent disease, so-called masked PV (mPV). It has been shown that mPV can be recognized in patients not meeting the required HB or HCT threshold levels by both the WHO and BCSH criteria. These cases present with the same baseline clinical features as overt PV but present worsened survival. A critical reappraisal of the WHO criteria may suggest either to reduce the thresholds for HB or to consider HCT values as major diagnostic criterion, as in the BCSH, in association with JAK2V617F mutation.
    [Show full text]